|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque显示文摘 | Bonderman D Teml A Jakowitsch J | 2002 | Blood2002，99，： | 1 |
| 2 | A prospective,open-label trial of 6-thioguanine in patients with ulcerative or indeterminate colitis显示文摘 | Teml A Schwab M Harrer M | | 0，，10： | 1 |
| 3 | Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque 显示文摘 | Bonderman D Teml A Jakowitsch J | 2002 | Blood2002，99，8： | 1 |
| 4 | The Arabidopsis CBF gene family is composed of three genes encoding AP2 domain - containing proteins whose expression is regulated by low temperature but not by abscisic acid or dehydration 显示文摘 | Medina J Bargues M Teml J | 1999 | Plant Physiology1999，119，： | 1 |
| 5 | Coronary no-reflow iscaused by shedding of active tissue factor from dissectedatherosclerotic plaque显示文摘 | Bonderman D Teml A Jakowitsch J | 2002 | Blood2002，99，8： | 1 |
| 6 | Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing 显示文摘 | Teml A Schaeffeler E Herrlinger KR | 2007 | Clin Pharmacokinet2007，46，3： | 1 |
| 7 | Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque显示文摘 | Bonderman D Teml A Jakowitsh J | 2002 | Blood2002，99，： | 1 |
| 8 | Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque显示文摘 | Bonderman D teml A Jakowitseh J | | 0，，08： | 1 |
| 9 | Universal bases and greedy algorthms for anisotropic function classes显示文摘 | TEML YAKOV V N | 2002 | Constructive Approximation2002，18，： | 1 |
| 10 | Clinical pharmacokinetics and use of infliximab 显示文摘 | Klotz U Teml A Schwab M | | Clin Pharmacokinet0，46，8： | 1 |
| 11 | Coronary no-reflow is caused by shedding of active tissue factor from dissected at herosclerotic plaque显示文摘 | Bonderman D Teml A Jakowitsch J | 2002 | Blood2002，99，： | 1 |
| 12 | Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmaeogenetieally guided dosing 显示文摘 | Teml A Schaeffeler E Herrlinger KR | 2007 | Clin Pharmacokinet2007，46，： | 1 |
| 13 | Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotie plaque显示文摘 | Bonderman D Teml A Jakowitseh J | 2002 | Blood2002，99，： | 1 |
| 14 | Coronary no-reflow is c- aused by shedding of active tissue factor from dissected atheroscle- rotic plaques 显示文摘 | Bonderman D Teml A Jakowitsch J | 2002 | J Blood2002，99，8： | 1 |
| 15 | Adherence to thiopu- rine treatment in out-patients with Crohn's disease显示文摘 | Bokemeyer B Teml A Roggel C | 2007 | Ali- ment Pharmaeol Ther2007，26，2： | 1 |
| 16 | A systematic survey evaluating 6-thioguanine-related hepatotoxicity in patients with inflammatory bowel disease显示文摘 | Alexander Teml Matthias Schwab Daan W. Hommes Sven Almer Milan Lukas Thomas Feichtenschlager Timothy Florin Julia Seiderer Wolfgang Petritsch Bernd Bokemeyer Wolfgang Kreisel Klaus R. Herrlinger Peter Knoflach Bruno Bonaz Thomas Klugmann Hans Herfarth Nik | 2007 | Wiener klinische Wochenschrift (-)2007，，17： | 1 |
| 17 | 6-硫鸟嘌呤治疗溃疡性或不确定性结肠炎:一项前瞻性、公开标识试验显示文摘Objective. 6-thioguanine (6-TG) has emerged as a pro-mising therapeutic alternative in patients with Crohn’ s disease intolerant or resistant to azathioprine (AZA) and/or 6-mercaptopurine (6-MP). The aim of the present study was to evaluate the safety and efficacy of 6-TG in patients with ulcerative colitis (UC) or indeterminate colitis (IC) intolerant or resistant to AZA/6-MP. Material and methods. Twenty patients with an acute flare, steroid-dependent or steroid-refractory disease attending our outpatient department were included in the study. Measurement of 6-TG nucleotide levels was done to check compliance. Complete, partial and non-response were defined by means of the clinical activity index and the daily steroid demand. Secondary outcome parameters included changes in cumulative steroid doses, C-reactive protein (CRP) levels, and an endoscopic score. Results. Out of 20 patients 4 were excluded owing to incompliance; 2/16 compliant patients (13% ) had to be prematurely withdrawn because of adverse events, which ceased upon drug discontinuation. By per-protocol analysis, 5/14 patients (36% )were complete, 6/14 (43% ) partial and 3/14 (21% ) non-responders. In addition to the reduction of the cumulative steroid dose over 3 months, CRP decreased in the study population and the endoscopic score decreased in treatment responders. Conclusions. Treatment with 6-TG was effective in patients with UC or IC previously intolerant or resistant to AZA/6-MP. Future work is needed to define a subpopulation of patients at low risk for its potential hepatotoxicity, which we assume will benefit from 6-TG. | Teml A. Schwab M. Harrer M. W. Reinisch 赵天智 | 2006 | 世界核心医学期刊文摘(胃肠病学分册)2006，2，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员